Predicting the outcome of ankylosing spondylitis therapy

Predicting the outcome of ankylosing spondylitis therapy

Objectives To create a model that provides a potential basis for candidate selection for anti-tumour necrosis factor (TNF) treatment by predicting future outcomes relative to the current disease profile of individual patients with ankylosing spondylitis (AS). Methods ASSERT and GO–RAISE trial data (...

Descripció completa

Guardat en:

Dades bibliogràfiques
Autors principals:	Nathan Vastesaeger, Désirée van der Heijde, Robert D. Inman, Yanxin Wang, Atul Deodhar, Benjamin Hsu, Mahboob U. Rahman, Ben A. C. Dijkmans, Piet Geusens, Bert Vander Cruyssen, Eduardo Collantes‐Estévez, Joachim Sieper, Jürgen Braun
Format:	Artigo
Idioma:	anglès
Publicat:	2011
Accés en línia:	https://doi.org/10.1136/ard.2010.147744 https://ard.bmj.com/content/annrheumdis/70/6/973.full.pdf
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars

Predicting the outcome of ankylosing spondylitis therapy
per: Vastesaeger, Nathan, et al.
Publicat: (2011)

Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery
per: Bert Vander Cruyssen, et al.
Publicat: (2009)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
per: van der Heijde, Désirée, et al.
Publicat: (2019)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
per: Désirée van der Heijde, et al.
Publicat: (2018)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
per: Braun, Jürgen, et al.
Publicat: (2011)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
per: Jürgen Braun, et al.
Publicat: (2011)

Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab
per: Wagner, Carrie, et al.
Publicat: (2011)

Ankylosing spondylitis: an overview
per: Joachim Sieper, et al.
Publicat: (2002)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
per: Deodhar, Atul, et al.
Publicat: (2015)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
per: Atul Deodhar, et al.
Publicat: (2014)

Anti-tumour necrosis factor α therapy for ankylosing spondylitis: international experience
per: Braun, J, et al.
Publicat: (2002)

The Effect of Golimumab Therapy on Disease Activity and Health-related Quality of Life in Patients with Ankylosing Spondylitis: 2-year Results of the GO-RAISE Trial
per: Désirée van der Heijde, et al.
Publicat: (2014)

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
per: Dominique Baeten, et al.
Publicat: (2015)

First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis
per: Jürgen Braun, et al.
Publicat: (2005)

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
per: Jürgen Braun, et al.
Publicat: (2011)

Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis
per: Jürgen Braun, et al.
Publicat: (2023)

Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study
per: Inman, Robert D., et al.
Publicat: (2016)

Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study
per: Xenofon Baraliakos, et al.
Publicat: (2023)

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
per: Braun, Jürgen, et al.
Publicat: (2014)

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
per: Jürgen Braun, et al.
Publicat: (2013)

The epidemiology of ankylosing spondylitis and the commencement of anti‐TNF therapy in daily rheumatology practice
per: Cruyssen, Bert Vander, et al.
Publicat: (2007)

The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice
per: Bert Vander Cruyssen, et al.
Publicat: (2007)

Spinal Radiographic Changes in Ankylosing Spondylitis: Association with Clinical Characteristics and Functional Outcome
per: Annelies Boonen, et al.
Publicat: (2009)

Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
per: Braun, Jürgen, et al.
Publicat: (2018)

The epidemiology of osteoporosis and fractures in ankylosing spondylitis
per: Sambrook, Philip N., et al.
Publicat: (2012)

The epidemiology of osteoporosis and fractures in ankylosing spondylitis
per: Philip N. Sambrook, et al.
Publicat: (2012)

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
per: Braun, Jürgen, et al.
Publicat: (2011)

ASAS/EULAR recommendations for the management of ankylosing spondylitis
per: Zochling, J, et al.
Publicat: (2006)

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
per: Désirée van der Heijde, et al.
Publicat: (2022)

Etanercept in the Longterm Treatment of Patients With Ankylosing Spondylitis
per: Ben A. C. Dijkmans, et al.
Publicat: (2009)

Ankylosing spondylitis: an overview
per: Sieper, J, et al.
Publicat: (2002)

Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis
per: Sudha Visvanathan, et al.
Publicat: (2008)

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
per: Braun, J, et al.
Publicat: (2011)

Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches.
per: Jürgen Braun, et al.
Publicat: (2002)

Definition of disease duration in ankylosing spondylitis: reassessing the concept
per: Davis, J C, et al.
Publicat: (2006)

Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis
per: Désirée van der Heijde, et al.
Publicat: (2007)

Staging of patients with ankylosing spondylitis: a preliminary proposal
per: Braun, J, et al.
Publicat: (2002)

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
per: Désirée van der Heijde, et al.
Publicat: (2008)

Determinants of hyperkyphosis in patients with ankylosing spondylitis
per: Vosse, D, et al.
Publicat: (2006)

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
per: Jürgen Braun, et al.
Publicat: (2016)